Taiwan Liposome Company, Ltd. (TLC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Taiwan Liposome Company, Ltd. (TLC) trades at $7.00 with AI Score 53/100 (Grade B). Taiwan Liposome Company, Ltd. (TLC) is a biopharmaceutical company specializing in the development of novel nanomedicines. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TLC: TLC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TLC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TLC: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Taiwan Liposome Company, Ltd. (TLC) Healthcare & Pipeline Overview
Taiwan Liposome Company, Ltd. (TLC), an ADR traded in the US, focuses on developing innovative nanoliposomal drug delivery systems to enhance the therapeutic efficacy and safety of pharmaceutical products, primarily targeting unmet needs in oncology and pain management within the broader biotechnology sector.
What Is the Investment Thesis for TLC?
TLC presents a compelling investment thesis based on its innovative NanoX™ drug delivery platform and promising pipeline of nanoliposomal therapeutics. Key value drivers include the potential for regulatory approvals and commercialization of its lead product candidates, such as TLC599 for osteoarthritis pain and TLC179 for cancer therapy. Upcoming clinical trial results and potential partnerships with larger pharmaceutical companies represent significant growth catalysts. However, the company's negative profit margin of -964.7% and reliance on future product approvals pose considerable risks. Successful execution of clinical trials and securing regulatory approvals are critical for realizing the company's long-term value.
Based on FMP financials and quantitative analysis
TLC Key Highlights
Gross Margin of 100.0% reflects the potential profitability of TLC's products upon commercialization, although this is offset by high R&D expenses currently.
- Beta of 0.80 indicates lower volatility compared to the overall market, suggesting a degree of stability in the stock price.
- Focus on nanoliposomal drug delivery systems positions TLC in a high-growth area of the biotechnology industry.
- ADR structure provides US investors with access to a Taiwanese biotechnology company.
- Pipeline of product candidates targeting significant unmet needs in pain management and oncology.
Who Are TLC's Competitors?
TLC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301M | 60 |
| CATB Catabasis Pharmaceuticals, Inc. | $8.54 | -6.97% | $235M | 45 |
| CBLI Cytocom, Inc. | $3.17 | -7.31% | $226M | 50 |
| CELU Celularity Inc. | $0.77 | -1.41% | $22.2M | — |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $242.61 | +6.12% | $32.5B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLC's Key Strengths?
Proprietary NanoX™ drug delivery platform.
- Expertise in nanoliposomal formulation and manufacturing.
- Pipeline of product candidates targeting unmet medical needs.
- Potential for improved drug efficacy and safety.
What Are TLC's Weaknesses?
Negative profit margin and reliance on future product approvals.
- Limited commercial infrastructure.
- Dependence on partnerships for commercialization.
- High R&D expenses.
What Could Drive TLC Stock Higher?
Clinical trial results for TLC599 in osteoarthritis pain (expected Q4 2026).
- Regulatory submission for TLC179 in a specific cancer indication (expected H1 2027).
- Potential partnerships with pharmaceutical companies for commercialization of TLC's products.
- Expansion of the NanoX™ platform to develop new drug candidates.
What Are the Key Risks for TLC?
Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Clinical trial failures and regulatory rejections.
- Competition from other drug delivery technologies.
- Patent expiration and generic competition.
- Dependence on partnerships for commercialization.
- Currency fluctuations affecting the value of the ADR.
What Are the Growth Opportunities for TLC?
- Expansion of TLC599 into additional indications: TLC599, a sustained-release formulation of pain medication, has the potential to address unmet needs in various pain management indications beyond osteoarthritis. Expanding clinical trials to include indications such as post-operative pain or chronic back pain could significantly increase the market opportunity. The global pain management market is projected to reach $83 billion by 2027, providing a substantial addressable market for TLC599.
- Development of TLC179 for additional cancer types: TLC179, a nanoliposomal formulation for cancer therapy, can be further developed for other cancer types beyond its initial target. Expanding the clinical program to include cancers with high unmet needs, such as pancreatic cancer or glioblastoma, could significantly broaden its market potential. The global oncology market is expected to reach $286 billion by 2028.
- Strategic partnerships with pharmaceutical companies: Collaborating with larger pharmaceutical companies for the development and commercialization of TLC's products can provide access to resources and expertise. Partnering with companies specializing in specific therapeutic areas, such as oncology or pain management, could accelerate the development and commercialization process. Strategic partnerships can also provide non-dilutive funding and validation of TLC's technology.
- Expansion into new geographic markets: Expanding commercial operations beyond the United States and Asia can unlock new revenue streams. Targeting markets with growing healthcare expenditures and unmet medical needs, such as Europe or Latin America, could significantly increase the company's global reach. However, navigating regulatory requirements and establishing distribution networks in new markets will be critical for success.
- Leveraging the NanoX™ platform for new drug development: TLC's proprietary NanoX™ platform can be used to develop new nanoliposomal formulations of existing and new chemical entities. Identifying promising drug candidates and formulating them using the NanoX™ platform can create a pipeline of novel therapeutics. This approach can leverage the platform's advantages in improving drug bioavailability, reducing toxicity, and enhancing targeted drug delivery.
What Are TLC's Competitive Advantages?
- Proprietary NanoX™ drug delivery platform.
- Expertise in nanoliposomal formulation and manufacturing.
- Pipeline of product candidates with clinical data.
- Intellectual property protection through patents and trade secrets.
What Does TLC Do?
Taiwan Liposome Company, Ltd. (TLC), headquartered in Taipei, Taiwan, is a specialty pharmaceutical company dedicated to the research, development, and commercialization of innovative nanomedicines. Founded with the vision of revolutionizing drug delivery, TLC leverages its proprietary lipid-based technology platform, known as NanoX™, to create novel formulations of existing and new chemical entities. These nanoliposomal formulations are designed to improve drug bioavailability, reduce toxicity, and enhance targeted drug delivery to specific tissues or cells. TLC's core expertise lies in developing sustained-release and targeted drug delivery systems that address unmet medical needs across various therapeutic areas. The company's pipeline includes products targeting pain management, oncology, and infectious diseases. TLC's geographic focus is primarily on the United States and Asia. TLC operates in the competitive biotechnology landscape, facing competition from both large pharmaceutical companies and smaller biotech firms developing drug delivery technologies. TLC strives to differentiate itself through its NanoX™ platform and its focus on developing clinically differentiated products.
What Products and Services Does TLC Offer?
- Develops nanoliposomal drug delivery systems.
- Creates novel formulations of existing and new chemical entities.
- Improves drug bioavailability and reduces toxicity.
- Enhances targeted drug delivery to specific tissues or cells.
- Focuses on therapeutic areas such as pain management and oncology.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Seeks regulatory approvals for its products from health authorities.
- Commercializes its products through partnerships or direct sales.
How Does TLC Make Money?
- Develops proprietary nanoliposomal drug delivery technology (NanoX™).
- Creates enhanced formulations of existing drugs and novel compounds.
- Out-licenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does TLC Operate In?
TLC operates within the biotechnology industry, which is characterized by high growth potential, rapid innovation, and intense competition. The market for drug delivery systems is expanding, driven by the need for more effective and safer therapies. TLC's focus on nanoliposomal drug delivery positions it within a specialized segment of this market. Key competitors include companies developing alternative drug delivery technologies and larger pharmaceutical companies with established market presence. The industry is subject to stringent regulatory requirements and lengthy drug development timelines.
Who Are TLC's Key Customers?
- Pharmaceutical companies seeking to improve their drug products.
- Patients suffering from conditions treatable with TLC's products.
- Healthcare providers who prescribe TLC's products to their patients.
- Research institutions interested in using TLC's technology for drug development.
Earnings Track Record
Taiwan Liposome Company, Ltd. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 36.5% below estimates on average.
TLC Valuation & Market Position
Relative to its peer group, TLC's quantitative score of 53/100 is roughly in line with the peer average of 58/100.
Key Financial Metrics
Return on assets is -56.2%, showing how much profit it generates from its asset base. A current ratio of 4.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.1%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Taiwan Liposome Company, Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Taipei, TW. The company is led by CEO Keelung Hong. TLC has traded publicly since 2018.
TLC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary NanoX™ drug delivery platform.
- Expertise in nanoliposomal formulation and manufacturing.
- Pipeline of product candidates targeting unmet medical needs.
- Potential for improved drug efficacy and safety.
Bear Case
- Negative profit margin and reliance on future product approvals.
- Limited commercial infrastructure.
- Dependence on partnerships for commercialization.
- High R&D expenses.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TLC Latest News
No recent news available for TLC.
TLC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLC.
Price Targets
Wall Street price target analysis for TLC.
TLC MoonshotScore
What does this score mean?
The MoonshotScore rates TLC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Keelung Hong
Chief Executive Officer
Keelung Hong serves as the Chief Executive Officer of Taiwan Liposome Company, Ltd. He has extensive experience in the pharmaceutical and biotechnology industries. His background includes leadership roles in research and development, business development, and commercial operations. He has a proven track record of driving innovation and growth in the healthcare sector.
Track Record: Under Keelung Hong's leadership, Taiwan Liposome Company, Ltd. has advanced its pipeline of nanoliposomal therapeutics and secured strategic partnerships. He has overseen the company's clinical development programs and guided the company through regulatory milestones. His strategic vision has positioned TLC as a leader in the field of nanomedicine.
Taiwan Liposome Company, Ltd. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. TLC, as an ADR, allows U.S. investors to easily invest in Taiwan Liposome Company, Ltd. without the complexities of cross-border transactions. The depositary bank holds the actual shares in Taiwan and issues ADRs representing those shares to U.S. investors.
- Home Market Ticker: Taipei Exchange (TPEx), Taiwan
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Taiwan Liposome Company, Ltd. (TLC) — Healthcare
What does the AI Score mean for TLC?
TLC holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Taiwan Liposome Company, Ltd. (TLC) is a biopharmaceutical company specializing in the development of novel nanomedicines. Utilizing its proprietary lipid-based drug delivery system, TLC aims …
What does Taiwan Liposome Company, Ltd. do?
Taiwan Liposome Company, Ltd. (TLC) is a biopharmaceutical company specializing in the research, development, and commercialization of innovative nanomedicines. TLC utilizes its proprietary NanoX™ platform, a lipid-based drug delivery system, to create novel formulations of existing and new chemical entities.
What do analysts say about TLC stock?
Analyst coverage of TLC is limited, but the general sentiment is cautiously optimistic due to the potential of its NanoX™ drug delivery platform and pipeline of nanoliposomal therapeutics. Key valuation metrics are difficult to assess given the company's current lack of profitability.
What are the main risks for TLC?
The main risks for TLC include clinical trial failures, regulatory hurdles, competition from other drug delivery technologies, patent expiration, and dependence on partnerships for commercialization. Clinical trial failures could significantly delay or halt the development of its product candidates. Regulatory hurdles and lengthy drug development timelines can increase costs and delay market entry.
What revenue streams does Taiwan Liposome Company, Ltd. have in healthcare?
Currently, Taiwan Liposome Company, Ltd. primarily relies on revenue from licensing agreements, milestone payments, and research grants. As the company progresses its pipeline, potential revenue streams include product sales, royalties from partnered products, and contract manufacturing. The success of TLC's revenue diversification hinges on the clinical and regulatory success of its lead drug candidates, particularly TLC599 and TLC179, and the establishment of strategic partnerships for commercialization.
How does Taiwan Liposome Company, Ltd. manage patent expiration risks?
Taiwan Liposome Company, Ltd. mitigates patent expiration risks through a multi-faceted approach. This includes actively pursuing new patents for novel formulations and delivery methods utilizing its NanoX™ platform. The company also focuses on developing proprietary manufacturing processes and trade secrets to maintain a competitive advantage even after patent expiration. Furthermore, TLC strategically pursues follow-on innovations and new clinical applications for its existing products to extend their market exclusivity and lifecycle.
What are the key factors to evaluate for TLC?
Taiwan Liposome Company, Ltd. (TLC) holds an AI score of 53/100 (moderate). TLC presents a compelling investment thesis based on its innovative NanoX™ drug delivery platform and promising pipeline of nanoliposomal therapeutics. Not financial advice.
How frequently does TLC data refresh on this page?
TLC's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TLC's recent stock price performance?
Taiwan Liposome Company, Ltd. (TLC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary NanoX™ drug delivery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and based on available information.
- Analyst sentiment is based on limited coverage and may not be representative of the broader market.
- Future performance is subject to significant risks and uncertainties.